Brilinta
Merck’s vorapaxar fails in late-stage trial
November 15, 2011ACS, Brilinta, Efient, Merck, Plavix, antiplatelet, vorapaxar
Merck’s novel blood thinner vorapaxar has failed to meet its primary endpoint in a late-stage study.The TRACER trial compared vorapaxar …
FDA approves AstraZeneca’s Brilinta after delay
July 21, 2011Sales and Marketing AstraZeneca, Brilinta, Brilique, antiplatelet
The FDA has finally approved AstraZeneca’s oral blood thinner Brilinta after asking for more information on the drug last year. …
FDA delays approval of AstraZeneca’s Brilinta
December 20, 2010Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome
US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …
AZ plans heart attack study for Brilique
October 8, 2010Research and Development, Sales and Marketing AstraZeneca, Brilinta, Brilique
AstraZeneca is due to begin enrolling patients into a new study of its oral antiplatelet Brilique (ticagrelor) before the end …
AZ’s antiplatelet recommended for European approval
September 27, 2010Sales and Marketing Brilinta, Brilique, Brillinta, Possia
AstraZeneca’s oral antiplatelet treatment Brilique has received a positive opinion from a key European advisory committee. A marketing authorisation for …
Latest content
FibroFind appoints Lee Borthwick as CEO
